Chinese Drugmakers Explore AI Marketing Amid Anti-Graft Scrutiny

Reuters reported on November 11, 2026 that pharmaceutical companies in China are exploring marketing through medical AI assistants and customized disease-specific academic platforms as stricter anti-graft scrutiny reshapes drug promotion.

Read the full story at Unite.AI ↗

Timeline · 1 report

2026-11-11 12:09 · Unite.AI
Drugmakers in China Explore AI Marketing Amid Anti-Graft Scrutiny

More stories

Anthropic IPO valuation could reach $1.4-1.5 trillion as demand surges — CNBC Technology
OpenAI launches Businesses in ChatGPT beta with verified profiles and Business Agents — OpenAI News
Nvidia spy scandal exposes Singapore networks in China's AI chip trade — New York Times AI
OpenAI's quarterly revenue hits $10 billion, up about 50%, but losses persist — The Information AI
AI data center buildout seen continuing through 2028 as fiber shortage strains other sectors — DigiTimes Asia
Developers share workflows for running Claude Code and Codex together — r/ClaudeAI
AI training startup Mercor raises $750M Series D at $20B valuation — Economic Times Tech
Microsoft researchers show AI agents can be backdoored by editing fewer than 10 dormant neurons — Microsoft Research Blog

Get the daily brief of stories like this at 6:30 every morning →